Seguir
Anshuman Panda
Anshuman Panda
Rutgers Cancer Institute of New Jersey
Dirección de correo verificada de cinj.rutgers.edu
Título
Citado por
Citado por
Año
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
JM Mehnert, A Panda, H Zhong, K Hirshfield, S Damare, K Lane, L Sokol, ...
The Journal of clinical investigation 126 (6), 2334-2340, 2016
3612016
Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
CC Smith, KE Beckermann, DS Bortone, AA De Cubas, LM Bixby, SJ Lee, ...
The Journal of clinical investigation 128 (11), 4804-4820, 2019
2382019
Immune activation and benefit from avelumab in EBV-positive gastric cancer
A Panda, JM Mehnert, KM Hirshfield, G Riedlinger, S Damare, ...
JNCI: Journal of the National Cancer Institute 110 (3), 316-320, 2018
1832018
Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma
A Panda, AA de Cubas, M Stein, G Riedlinger, J Kra, T Mayer, CC Smith, ...
JCI insight 3 (16), 2018
1412018
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors
A Panda, A Betigeri, K Subramanian, JS Ross, DC Pavlick, S Ali, ...
JCO Precision Oncology 1, 1-13, 2017
702017
DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer
AA de Cubas, W Dunker, A Zaninovich, RA Hongo, A Bhatia, A Panda, ...
JCI Insight 5 (11), 2020
482020
Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma
SS Bjørklund, A Panda, S Kumar, M Seiler, D Robinson, J Gheeya, M Yao, ...
Scientific Reports 7 (1), 5568, 2017
422017
Genomic and immunologic correlates of LAG-3 expression in cancer
A Panda, JA Rosenfeld, EA Singer, G Bhanot, S Ganesan
OncoImmunology 9 (1), 1756116, 2020
262020
Tissue-and development-stage–specific mRNA and heterogeneous CNV signatures of human ribosomal proteins in normal and cancer samples
A Panda, A Yadav, H Yeerna, A Singh, M Biehl, M Lux, A Schulz, T Klecha, ...
Nucleic acids research 48 (13), 7079-7098, 2020
182020
The modular adaptive ribosome
A Yadav, A Radhakrishnan, A Panda, A Singh, H Sinha, G Bhanot
PloS one 11 (11), e0166021, 2016
152016
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016
A Lundqvist, V van Hoef, X Zhang, E Wennerberg, J Lorent, K Witt, ...
Journal for immunotherapy of cancer 4, 1-106, 2016
102016
SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis
K Tong, OA Kothari, KS Haro, A Panda, MM Bandari, JN Carrick, JJ Hur, ...
Oncogene 40 (41), 6034-6048, 2021
92021
Genomic and immunologic correlates of indoleamine 2, 3-dioxygenase pathway expression in cancer
A Panda, S Ganesan
Frontiers in Genetics 12, 706435, 2021
82021
Barrett’s Epithelium to Esophageal Adenocarcinoma: Is There a “Point of No Return”?
A Panda, M ryung Shin, C Cheng, M Bajpai
Frontiers in Genetics 12, 2021
72021
Recurring Translocations in Barrett’s Esophageal Adenocarcinoma
M Bajpai, A Panda, K Birudaraju, J Van Gurp, A Chak, KM Das, P Javidian, ...
Frontiers in Genetics 12, 813, 2021
32021
Gene Expression in Barrett’s Esophagus Cell Lines Resemble Esophageal Squamous Cell Carcinoma Instead of Esophageal Adenocarcinoma
A Panda, G Bhanot, S Ganesan, M Bajpai
Cancers 13 (23), 5971, 2021
32021
Expression of endogenous retroviruses and response to immune checkpoint therapy in renal cell cancer.
A Panda, A De Cubas, K Beckermann, G Riedlinger, MN Stein, TM Mayer, ...
Journal of Clinical Oncology 36 (5_suppl), 104-104, 2018
32018
Role for immune checkpoint blockade in BRCA2-mutant prostate cancer.
A Panda, MN Stein, G Riedlinger, G Bhanot, S Ganesan
Journal of Clinical Oncology 37 (8_suppl), 59-59, 2019
22019
Abstract PR05: Exceptional Response to PD-1 antibody treatment in a POLE-mutant endometrial cancer
JM Mehnert, A Panda, H Zhong, KM Hirshfield, S Damare, K Stiles, ...
Molecular Cancer Therapeutics 14 (12_Supplement_2), PR05-PR05, 2015
22015
Mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
S Ganesan, G Bhanot, JM Mehnert, AW Silk, JS Ross, D Pavlick, SM Ali, ...
Journal of Clinical Oncology 35 (7_suppl), 35-35, 2017
12017
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20